Stock Financial Ratios, Dividends, Split History

ETSY / Etsy, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)5,309.49
Enterprise Value ($M)4,896.49
Book Value ($M)384.49
Book Value / Share3.22
Price / Book13.43
NCAV ($M)219.32
NCAV / Share1.84
Price / NCAV23.55
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 118,538,687
Weighted Average Number Of Diluted Shares Outstanding 122,267,673
Common Shares Outstanding 121,502,754
Common Stock Shares Outstanding 121,769,238
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.21
Return on Assets (ROA)0.14
Return on Equity (ROE)0.24
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio6.62
Income Statement (mra) ($M)
Revenue Listing Fee Per Item0.20
Sales Revenue Net441,231,000.00
Operating Income11.90
Net Income81.80
Earnings Per Share Basic0.69
Earnings Per Share Diluted0.68
Cash Flow Statement (mra) ($M)
Cash From Operations67.42
Cash from Investing61.84
Cash from Financing61.84
Identifiers and Descriptors
Central Index Key (CIK)1370637
Related CUSIPS
29786A906 29786A956

Split History

Stock splits are used by Etsy, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

5 Internet Stocks Set to Outperform in Q2 Earnings

2018-07-19 investorplace
Internet stocks had a terrific first half of 2018, thanks to growing number of Internet users, improving speed & penetration, rapid adoption of 4G Volte technology, increasing demand for videos and proliferation of online retail. (41-0)

Is Etsy (ETSY) Stock Outpacing Its Computer and Technology Peers This Year?

2018-07-19 zacks
Investors focused on the Computer and Technology space have likely heard of Etsy (ETSY - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out. (3-0)

Is Etsy (ETSY) Outperforming Other Computer and Technology Stocks This Year?

2018-07-19 zacks
Investors interested in Computer and Technology stocks should always be looking to find the best-performing companies in the group. Etsy (ETSY - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of ETSY and the rest of the Computer and Technology group's stocks. (3-0)

Zacks Market Edge Highlights: Align, Alibaba, Microsoft, Etsy and Amazon

2018-07-19 zacks
Chicago, IL – July 19, 2018 – Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here: ( (6-0)

eBay (EBAY) Beats Q2 Earnings Estimates, Misses on Revenues

2018-07-19 zacks
eBay Inc.’s (EBAY - Free Report) second-quarter 2018 earnings surpassed the Zacks Consensus Estimate by 2 cents. Pro-forma earnings of 53 cents improved 18% year over year. (5-0)

CUSIP: 29786A106